Jennison Associates Portfolio holdings
Jennison Associates, founded in 1969 and headquartered in New York City, is a global investment management firm managing over $194 billion in assets as of late 2024, specializing in active equity and fixed-income strategies. A subsidiary of PGIM, the asset management arm of Prudential Financial, Jennison serves a diverse client base—including institutions, sub-advisory clients, public plans, endowments, and corporations—with a focus on fundamental research, bottom-up portfolio construction, and high-conviction investing. Known for its equity expertise across styles, geographies, and market capitalizations, as well as investment-grade fixed-income offerings, the firm employs seasoned portfolio managers averaging 29 years of industry experience and 16 years with Jennison. With additional offices in Boston and a culture emphasizing intellectual rigor and long-term client outcomes, Jennison has built a reputation for excellence and stability in the investment management industry.
Top Buys
| 1 |
Microsoft
MSFT
|
+$447M |
| 2 |
Bath & Body Works
BBWI
|
+$338M |
| 3 |
Home Depot
HD
|
+$277M |
| 4 |
GE Aerospace
GE
|
+$267M |
| 5 |
Palo Alto Networks
PANW
|
+$236M |
Top Sells
| 1 |
LNKD
LinkedIn Corporation
LNKD
|
+$714M |
| 2 |
ARMH
ARM HOLDINGS PLC ADS
ARMH
|
+$414M |
| 3 |
Citigroup
C
|
+$376M |
| 4 |
Sherwin-Williams
SHW
|
+$292M |
| 5 |
Starbucks
SBUX
|
+$266M |
Sector Composition
| 1 | Consumer Discretionary | 20.49% |
| 2 | Healthcare | 16.68% |
| 3 | Communication Services | 14.23% |
| 4 | Technology | 14.03% |
| 5 | Financials | 9.24% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
476
Syndax Pharmaceuticals
SNDX
$1.47B
| $5.98M | 0.01% |
+460,892
| New | +$5.98M |
|
|
TRVN
477
DELISTED
Trevena, Inc.
TRVN
| $5.85M | 0.01% |
1,132
+8
| +0.7% | +$41.3K |
|
|
DMTX
478
DELISTED
Dimension Therapeutics, Inc
DMTX
| $5.83M | 0.01% |
745,801
+3,347
| +0.5% | +$26.1K |
|
|
WNRL
479
DELISTED
Western Refining Logistics, LP
WNRL
| $5.75M | 0.01% |
246,071
+40,344
| +20% | +$942K |
|
480
Editas Medicine
EDIT
$251M
| $5.7M | 0.01% |
+170,940
| New | +$5.7M |
|
|
LJPC
481
DELISTED
La Jolla Pharmaceutical Company
LJPC
| $5.2M | 0.01% |
+248,574
| New | +$5.2M |
|
482
Wave Life Sciences
WVE
$1.21B
| $5.12M | 0.01% |
370,825
+1,576
| +0.4% | +$21.7K |
|
483
Oneok
OKE
$44.9B
| $4.96M | 0.01% |
165,980
+29,438
| +22% | +$879K |
|
|
AVXS
484
DELISTED
AveXis, Inc. Common Stock
AVXS
| $4.9M | 0.01% |
+180,001
| New | +$4.9M |
|
|
FCSC
485
DELISTED
Fibrocell Science Inc.
FCSC
| $4.78M | 0.01% |
127,512
-60,290
| -32% | -$2.26M |
|
486
FerroAtlántica
GSM
$799M
| $4.71M | ﹤0.01% |
534,725
+24,954
| +5% | +$220K |
|
|
NS
487
DELISTED
NuStar Energy L.P.
NS
| $4.54M | ﹤0.01% |
112,455
+37,539
| +50% | +$1.52M |
|
|
DSCI
488
DELISTED
Derma Sciences, Inc. Common Stock (DE)
DSCI
| $4.39M | ﹤0.01% |
1,414,487
+6,981
| +0.5% | +$21.6K |
|
489
Exxon Mobil
XOM
$468B
| $4.35M | ﹤0.01% |
52,042
-197
| -0.4% | -$16.5K |
|
|
AM
490
DELISTED
ANTERO MIDSTREAM PARTNERS LP
AM
| $4.3M | ﹤0.01% |
194,582
+30,271
| +18% | +$669K |
|
|
TVRD
491
Tvardi Therapeutics, Inc. Common Stock
TVRD
$278M
| $4.11M | ﹤0.01% |
18,353
+118
| +0.6% | +$26.4K |
|
492
USA Compression Partners
USAC
$2.84B
| $4.04M | ﹤0.01% |
343,572
-12,249
| -3% | -$144K |
|
493
Norfolk Southern
NSC
$61.8B
| $3.98M | ﹤0.01% |
47,764
-471,049
| -91% | -$39.2M |
|
494
BioCryst Pharmaceuticals
BCRX
$1.72B
| $3.84M | ﹤0.01% |
1,357,604
+9,041
| +0.7% | +$25.6K |
|
|
GBT
495
DELISTED
Global Blood Therapeutics, Inc.
GBT
| $3.76M | ﹤0.01% |
237,317
-75,505
| -24% | -$1.2M |
|
496
MacroGenics
MGNX
$111M
| $3.68M | ﹤0.01% |
196,435
-70,973
| -27% | -$1.33M |
|
497
Qualys
QLYS
$4.88B
| $3.52M | ﹤0.01% |
138,894
-114,836
| -45% | -$2.91M |
|
498
Intel
INTC
$114B
| $3.34M | ﹤0.01% |
103,378
+2,794
| +3% | +$90.4K |
|
|
BCR
499
DELISTED
CR Bard Inc.
BCR
| $3.33M | ﹤0.01% |
+16,422
| New | +$3.33M |
|
500
Elevance Health
ELV
$69.4B
| $3.28M | ﹤0.01% |
23,598
-2,297
| -9% | -$319K |
|